TY - JOUR T1 - Reorganization of Substance Use Treatment and Harm Reduction Services during the COVID-19 Pandemic: A Global Survey JF - medRxiv DO - 10.1101/2020.09.21.20199133 SP - 2020.09.21.20199133 AU - Seyed Ramin Radfar AU - Cornelis A J De Jong AU - Ali Farhoudian AU - Mohsen Ebrahimi AU - Parnian Rafei AU - Mehrnoosh Vahidi AU - Masud Yunesian AU - Christos Kouimtsidis AU - Shalini Arunogiri AU - Omid Massah AU - Abbas Deylamizadeh AU - Kathleen T Brady AU - Anja Busse Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/22/2020.09.21.20199133.abstract N2 - Background The COVID-19 pandemic has impacted people with substance use disorders (SUDs) worldwide and healthcare systems have reorganized their services in response to the pandemic.Methods One week after the announcement of the COVID-19 as a pandemic, in a global survey, 177 addiction medicine professionals described COVID-19-related health responses in their own 77 countries in terms of SUD treatment and harm reduction services. The health response is categorized around (1) managerial measures and systems, (2) logistics, (3) service providers and (4) vulnerable groups.Results Respondents from over 88% of countries reported that core medical and psychiatric care for SUDs had continued; however, only 56% of countries reported having had any business continuity plan, and, 37.5% of countries reported shortages of methadone or buprenorphine supplies. Participants of 41% of countries reported partial discontinuation of harm-reduction services such as needle and syringe programs and condom distribution. 57% of overdose prevention interventions and 81% of outreach services also having been negatively impacted.Conclusions Participants reported that SUD treatment and harm reduction services had been significantly impacted globally early during the COVID-19 pandemic. Based on our findings, we provide a series of recommendations to support countries to be prepared more efficiently for future waves or similar pandemics to 1) help policymakers generate business continuity plans, 2) maintain use of evidence-based interventions for people with SUDs, 3) be prepared for adequate medication supplies, 4) integrate harm reduction programs with other treatment modalities and 5) have specific considerations for vulnerable groups such as immigrants and refugees.HighlightsCOVID-19 negatively impacted services for PWSUD globally.Addiction medicine downgraded more than other psychiatry services.Business continuity plan for PWSUD services reported only in about half of the countries.Refugees & migrants had more negative impact compared to other vulnerable groups.Harm reduction services discontinued partially or totally during pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols http://bcn.iums.ac.ir/article-1-1821-en.html Funding StatementNo funding to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The survey protocols and all materials, including the survey questionnaires, received approval from the University of Social Welfare and Rehabilitation Sciences, ethics committee in Tehran, Iran (Code: IR.USWR.REC.1399.061).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full description of the research design and analysis plan is available upon request. ER -